Page 6 - தீக்காயங்கள் ம்க்க்லெல்யாந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2) As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from baseline to week 26 in C3 glomerulopathy histologic index (C3G HI) for disease activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for disease chronicity (measuring progression of fibrosis) shows significant benefit for avacopan versus placebo Avacopan safe and well tolerated in C3G patients ChemoCentryx and VFMCRP plan to discuss registration pathway with regulatory agencies in US and EU Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005694/en/

United statesStephanie tomeiVifor pharmaJulien vignotSusanm kanayaDburns mcclellanNathalie ponnierStefan schulzeLee rothThomasj schallFresenius medicalSwiss stock exchangeEuropean commissionDrug administrationGlobal head corporate communicationsSwiss exchange